Clinical trials · Boston, MA
Acute Myeloid Leukemia, in Relapse clinical trials in Boston
We’re tracking 37 recruiting acute myeloid leukemia, in relapse studies with a site in or near Boston — including Phase 1, Phase 1/Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Boston
- NCT04065399RecruitingPhase 1/Phase 2
Testing revumenib for relapsed acute leukemia with certain gene changes
This trial tests revumenib, a targeted medicine, to treat acute leukemia that has come back or hasn’t fully gone away. It may help people whose leukemia has specific gene changes (like KMT2A or NPM1) by trying to better control the cancer.
Boston, MassachusettsAges 4 weeks+ - NCT05183035RecruitingPhase 3
Venetoclax for relapsed childhood AML
This trial studies venetoclax in children and young adults whose acute myeloid leukemia (AML) has come back. It aims to see how well this treatment controls the leukemia after earlier therapies.
Boston, MassachusettsAges 4 weeks–21 years - NCT05237258Recruiting
Compare palliative care approaches for people with high-risk AML
This study tests a specialized (targeted) palliative care program versus usual oncology care for people hospitalized with high-risk acute myeloid leukemia (AML). The goal is to see if this palliative approach improves comfort, support, and care planning during intensive treatment.
Boston, MassachusettsAges 18–120 - NCT04771572RecruitingPhase 1
Oral drug LP-118 for relapsed blood cancers
This Phase 1 study tests an oral (by mouth) drug called LP-118 in people whose blood cancers have returned or did not respond to prior treatment. The goal is to find a safe dose and see whether it can shrink or control the cancer.
Boston, MassachusettsAges 13 years+ - NCT04726241RecruitingPhase 1/Phase 2
Testing blood and bone marrow samples in young leukemia patients
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
Boston, MassachusettsAges Up to 22 years - NCT04988555RecruitingPhase 1/Phase 2
Study of an investigational drug for high-risk acute leukemia
This Phase 1/2 study tests enzomenib (DSP-5336) in people with relapsed or hard-to-treat acute leukemia (and, in some places, certain other blood cancers). The goal is to see how the drug works and how safe it is, especially for leukemia cases with specific genetic changes (KMT2A/MLL or NPM1).
Boston, MassachusettsAges 12 years+ - NCT05143996RecruitingPhase 1
First study drug for relapsed AML or MDS
This Phase 1 trial tests CLN-049 in adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or did not respond to treatment. The goal is to find out how well the drug can work and how safe it is in people with limited options.
Boston, MassachusettsAges 18 years+ - NCT05546580RecruitingPhase 1
Testing iadademstat plus gilteritinib for relapsed AML with FLT3 mutation
This Phase 1 study tests whether a new drug called iadademstat, combined with gilteritinib, can help people with relapsed or refractory AML that has certain FLT3 mutations. It’s mainly looking to find a safe dose and see early signs of effectiveness.
Boston, MassachusettsAges 18 years+ - NCT05292664RecruitingPhase 1
Venetoclax trial for high-risk blood cancers in young patients
This Phase 1 study tests venetoclax to treat certain high-risk blood cancers in children, teens, or young adults. It is designed to see if the drug can work safely for patients whose disease has returned or did not respond to prior treatment.
Boston, MassachusettsAges 1–40 - NCT05735184RecruitingPhase 1
Ziftomenib with AML medicines for NPM1- or KMT2A-mutated leukemia
This Phase 1 trial tests how safe and tolerable ziftomenib is when combined with standard AML medicines (like venetoclax and azacitidine, and other chemo options) in people with AML. It’s for AML patients who have specific genetic changes (NPM1 mutation or KMT2A rearrangement) and helps doctors find the best, safest dose plan.
Boston, MassachusettsAges 18 years+ - NCT06440135RecruitingPhase 1
Ziftomenib maintenance after stem cell transplant for AML
This trial tests if the drug ziftomenib can help prevent AML from coming back after a stem cell transplant. It is for people who have certain gene changes (KMT2A rearrangement or NPM1 mutation) and are in remission or near-remission before transplant.
Boston, MassachusettsAges 18 years+ - NCT05702645Recruiting
Down syndrome long-term study after leukemia treatment
This study follows children and young adults with Down syndrome who have survived acute leukemia (ALL or AML) to learn about their longer-term health after treatment ends. It may help families and doctors understand what health problems to watch for and how to provide better follow-up care.
Providence, Rhode IslandAges 6–39 - NCT06788756RecruitingPhase 2/Phase 3
Testing L-Annamycin plus Cytarabine for relapsed AML
This trial tests whether the combination of two chemotherapy drugs, L-Annamycin and Cytarabine, can help adults whose acute myeloid leukemia (AML) has come back or not responded to one prior treatment. The goal is to see if this combination can lead to remission.
Providence, Rhode IslandAges 18–80
Hear when a new Acute Myeloid Leukemia, in Relapse trial opens near Boston, MA
We’ll email you when one opens near Boston, MA — at most once a week, no account needed, unsubscribe anytime.
Acute Myeloid Leukemia, in Relapse trials in other cities
Where these studies are running near Boston
Institutions with a site for the recruiting acute myeloid leukemia, in relapse studies listed above.
- Dana-Farber Cancer Institute · 6 studies
- Massachusetts General Hospital · 6 studies
- Rhode Island Hospital · 2 studies
- Tufts University
- University of Massachusetts Chan Medical School
- University of Rhode Island
What taking part in a acute myeloid leukemia, in relapse study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting acute myeloid leukemia, in relapse studies in Massachusetts.
Common questions
- Are there acute myeloid leukemia, in relapse clinical trials near Boston?
- Yes. We're currently tracking 37 recruiting acute myeloid leukemia, in relapse studies with a site near Boston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a acute myeloid leukemia, in relapse study near Boston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Boston to take part?
- Not necessarily. These studies have a site near Boston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a acute myeloid leukemia, in relapse trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New acute myeloid leukemia, in relapse studies open near Boston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.